Micah Jackson, Worldview Wellness

The Joe Tippens Protocol is an alternative cancer regimen popularized by Joe Tippens, an American who was diagnosed with stage IV small-cell lung cancer in 2016. At the time, his prognosis was extremely poor, with doctors estimating a survival window of just months. Tippens was enrolled in a clinical trial for pembrolizumab (Keytruda), an immunotherapy drug, but he credits much of his remarkable recovery (achieving full remission and remaining cancer-free for over a decade as of 2026) to an unconventional add-on approach he adopted.

Inspired by a veterinarian’s suggestion and preclinical ideas about repurposed drugs, he began self-administering fenbendazole, a benzimidazole anthelmintic primarily used as a veterinary dewormer for parasites in animals. The core protocol typically involves taking approximately 222 mg of fenbendazole daily, sometimes cycled as three days on and four days off, combined with additional supportive supplements. These include bioavailable curcumin, CBD oil, and occasionally vitamin E or other additions like black cumin seed oil in variations. Tippens shared his story through his blog and on social media, sparking widespread interest and anecdotal reports from others who adopted similar regimens for various cancers, including lung, colorectal, pancreatic, prostate, and more.

While Tippens has remained active in discussing his experience and is confirmed alive and in remission in 2026, the protocol has evolved through online communities. I often encounter clients who ask about or have already self-started some version of the Joe Tippens protocol with some users adjusting doses or adding other anthelmintics like ivermectin. The truth about what I have personally seen in my experience as a cancer consultant despite the new encouraging science that has been done on repurposing these drugs for cancer is that the vast majority of these people do not see the same success that Joe Tippens did during his treatment, and almost none of these clients are aware that Joe Tippens was also taking Keytruda, which is now an approved conventional immunotherapy treatment.

The protocol is not a formally approved medical treatment, and Tippens has emphasized it as a personal story rather than universal advice, yet it has gained traction among those seeking options beyond conventional therapies.

The mechanisms of the Joe Tippens protocol in cancer are complex and multifactorial. I tried to keep it light here, but if you don’t want to geek out on the science you may want to skip this paragraph and move on to the next one. The purported mechanisms of the Joe Tippens protocol center primarily on fenbendazole’s potential anticancer effects, drawing from preclinical (in vitro and animal) studies on benzimidazoles. Fenbendazole is believed to disrupt microtubules by binding to β-tubulin, interfering with the formation of the mitotic spindle essential for cell division.

This leads to mitotic arrest (disruption of cell division/proliferation) in rapidly proliferating cancer cells, ultimately triggering apoptosis (programmed cell death), a process very similar to how certain chemotherapy agents like vincristine or paclitaxel function. Additional proposed actions include impairing glucose metabolism due to cancers’ heavy reliance on glycolysis (the Warburg effect) by blocking glucose uptake and reducing energy production, effectively starving tumors of fuel (specifically glucose/sugar which can be augmented with a ketogenic or other low-carb diet). Studies suggest fenbendazole may also induce oxidative stress, activate pathways like p53, interfere with mitochondrial function, and potentially inhibit angiogenesis (new blood vessel formation in tumors). Complementary supplements are thought to enhance these effects synergistically: curcumin modulates inflammatory and signaling pathways (e.g., NF-κB inhibition) that promote cancer survival, while CBD oil may support immune modulation, reduce inflammation, or aid in apoptosis.

In anecdotal accounts, including Tippens’ own narrative, this multi-pronged approach (fenbendazole as the primary agent plus supplements) is credited with tumor regression, improved scans, and sustained remission, even in advanced or treatment-resistant cases. Preclinical data on related benzimidazoles like mebendazole, and other anthelmintics like ivermectin show similar promise across cancer types, and some recent studies over the last few years have explored other beneficial mechanisms like ferroptosis, pyroptosis, or glycolysis suppression via hexokinase 2 downregulation among others. Proponents argue the protocol targets cancer metabolism and cellular infrastructure in ways that standard treatments might not, offering a low-cost, accessible option. However, these mechanisms remain largely hypothetical in humans (outside of anecdotal evidence like from Joe Tippens himself), are derived from lab and animal models rather than controlled clinical evidence, and generally do not include the fact that Tippens’ outcome occurred alongside immunotherapy, complicating attribution to the protocol alone at a minimum.

Despite the compelling anecdotes and preclinical intrigue, the Joe Tippens Protocol is not right for everyone with cancer, and self-administration carries significant risks that demand caution. Foremost among these is the potential for liver toxicity (hepatotoxicity), as fenbendazole and Ivermectin are metabolized primarily in the liver. My personal experience with clients who choose to self-guide the Joe Tippens protocol generally reflect the same patterns (although most of them less severe) of many case reports in the scientific literature documenting severe hepatocellular injury, including jaundice, elevated liver enzymes, and acute liver failure-like presentations, resolving only after discontinuation. For instance, an 80-year-old woman with non-small cell lung cancer developed profound liver damage after one month of use, while other oncology patients on immunotherapy experienced similar issues that mimicked drug-related hepatitis. Individuals with pre-existing impaired liver function common in cancers like hepatocellular carcinoma, metastatic disease affecting the liver, or those with cirrhosis, hepatitis, or prior chemotherapy are particularly vulnerable, as reduced hepatic clearance can lead to drug accumulation, amplified toxicity, and irreversible harm.

Surveys of users in regions like South Korea have noted liver abnormalities in a subset of self-administering patients, alongside gastrointestinal issues and potential hematological effects. Higher or prolonged doses that often occur with self-guided care will exacerbate these risks, and interactions with conventional treatments (e.g., chemotherapy or immunotherapy) remain poorly understood. Moreover, I would argue that without robust human clinical trial data the protocol risks delaying or interfering with evidence-based therapies that offer proven survival benefits. This is true regardless of one’s personal choice to engage in conventional treatment, metabolic terrain-based complementary/alternative treatment, or the integrative model which utilizes both. Organizations like the American Cancer Society and FDA (although generally not my favorite groups) rightly emphasize the absence of controlled data, warning against false hope and potential progression of disease that can occur due primarily to delayed onset of organized treatment, and lack of clinical oversight.

Although oncologists do monitor liver function tests (e.g., ALT, AST, bilirubin), they are largely hesitant to be onboard with or recommend the Joe Tippens protocol as they would then be responsible for adjusting for comorbidities, screening for interactions, and integrating any experimental use safely within a broader plan. In the current medical environment (post-covid era), there are multiple additional concerns a conventional clinician must consider with using off-label drugs including political/institutional kick-back, the lack of human data, and ignorance over compassionate use or complementary and alternative medicine use laws which are designed to ensure informed consent (which is definitely a good thing), but can also be quite clunky and confusing to navigate, especially for those in an institutional setting. If this is the case, it is absolutely essential to find a second opinion or functional consultant/clinician who can regularly assess your lab data in order to keep you out of harm’s way.

In short, the Joe Tippens protocol is circulating widely in the online environment largely due to a lack of trust in the conventional medical models’ approach to cancer, but relying solely on anecdotal success stories overlooks the necessary nuanced individual variability perspective in cancer biology, metabolism, and tolerance. While the protocol inspires hope and highlights drug repurposing potential, it is not a substitute for personalized, medically supervised care. Cancer treatment decisions should prioritize evidence, safety, and professional guidance to avoid unintended harm. So, is the Joe Tippens protocol right for you? Maybe… but maybe not. If you’re curious about finding out more about this and other topics in cancer, consider scheduling a consultation at worldviewwellness.com